Renal dysfunction in chronic hepatitis B patients treated with adefovir dipivoxil

Hepatology

Volumn 50, Issue 3, 2009, Pages 727-734

  Ha, Nghi B ^a   Ha, Nghiem B ^a,c   Garcia, Ruel T ^a,b   Trinh, Huy N ^a,b   Vu, Andrew A ^a   Nguyen, Huy A ^b   Nguyen, Khanh K ^b   Levitt, Brian S ^b   Nguyen, Mindie H ^c  

^a Pacific Health Foundation   (United States)

^b San Jose Gastroenterology   (United States)

^c STANFORD UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR DIPIVOXIL; CREATININE; ENTECAVIR; ADENINE; ANTIVIRUS AGENT; DRUG DERIVATIVE; PHOSPHONIC ACID DERIVATIVE;

ADULT; AGE DISTRIBUTION; ARTICLE; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; GLOMERULUS FILTRATION RATE; HEPATITIS B; HUMAN; HYPERTENSION; INCIDENCE; KIDNEY DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; POPULATION RESEARCH; PRIORITY JOURNAL; SEX DIFFERENCE; TREND STUDY; AGED; BLOOD; CHEMICALLY INDUCED DISORDER; CHRONIC KIDNEY FAILURE; COHORT ANALYSIS; KIDNEY FUNCTION TEST; MIDDLE AGED; RETROSPECTIVE STUDY;

ADENINE; ADULT; AGED; ANTIVIRAL AGENTS; COHORT STUDIES; CREATININE; FEMALE; GLOMERULAR FILTRATION RATE; HEPATITIS B, CHRONIC; HUMANS; KIDNEY FAILURE, CHRONIC; KIDNEY FUNCTION TESTS; MALE; MIDDLE AGED; PHOSPHONIC ACIDS; RETROSPECTIVE STUDIES;

EID: 70349230970     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.23044     Document Type: Article

References (21)

1. Lee WM. Hepatitis B virus infection. N Engl J Med 1997;337:1733-1745.
2. Lok AS, McMahon BJ. Chronic hepatitis B: update of recommendations. HEPATOLOGY 2004;39:857-861.
3. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Chang TT, Kitis G, Rizzetto M, et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology 2006;131:1743-1751. (Pubitemid 44958517)
4. Keeffe EB, Dieterich DT, Han SH, Jacobson IM, Martin P, Schiff ER, et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update. Clin Gastroenterol Hepatol 2008;6:1315-1341.
5. Dai CY, Chuang WL, Hsieh MY, Lee LP, Huang JF, Hou NJ, et al. Adefovir dipivoxil treatment of lamivudine-resistant chronic hepatitis B. Antiviral Res 2007;75:146-151. (Pubitemid 46669710)
6. Manesis EK, Hadziyannis SJ. Interferon alpha treatment and retreatment of hepatitis B e antigen-negative chronic hepatitis B. Gastroenterology 2001;121:101-109. (Pubitemid 32591519)
7. Lok AS, Lai CL, Leung N, Yao GB, Cui ZY, Schiff ER, et al. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology 2003;125:1714-1722. (Pubitemid 37500436)
8. Wai CT, Lok AS. Treatment of hepatitis B. J Gastroenterol 2002;37:771-778.
9. Lim SG, Marcellin P, Tassopoulos N, Hadziyannis S, Chang TT, Tong M, et al. Clinical trial: effects of adefovir dipivoxil therapy in Asian and Caucasian patients with chronic hepatitis B. Aliment Pharmacol Ther 2007;26:1419-1428. (Pubitemid 350045604)
10. Akyildiz M, Gunsar F, Ersoz G, Karasu Z, Ilter T, Batur Y, et al. Adefovir dipivoxil alone or in combination with lamivudine for three months in patients with lamivudine resistant compensated chronic hepatitis B. Dig Dis Sci 2007;52:3444-3447. (Pubitemid 350077178)
11. Izzedine H, Hulot JS, Launay-Vacher V, Marcellini P, Hadziyannis SJ, Currie G, et al. Renal safety of adefovir dipivoxil in patients with chronic hepatitis B: two double-blind, randomized, placebo-controlled studies. Kidney Int 2004;66:1153-1158. (Pubitemid 39121022)
12. Dando T, Plosker G. Adefovir dipivoxil: a review of its use in chronic hepatitis B. Drugs 2003;63:2215-2234. (Pubitemid 37289922)
13. Fung SK, Lok AS. Drug insight: nucleoside and nucleotide analog inhibitors for hepatitis B. Nat Clin Pract Gastroenterol Hepatol 2004;1:90-97.
14. Gilead Science I. Hepsera (adefovir dipivoxil) package insert. May 2008.
15. Levey AS, Coresh J, Balk E, Kausz AT, Levin A, Steffes MW, et al. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med 2003;139:137-147. (Pubitemid 38129105)
16. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999;130:461-470. (Pubitemid 29135798)
17. Lok AS, McMahon BJ. Chronic hepatitis B. HEPATOLOGY 2007;45:507-539.
18. Kahn J, Lagakos S, Wulfsohn M, Cherng D, Miller M, Cherrington J, et al. Efficacy and safety of adefovir dipivoxil with antiretroviral therapy: a randomized controlled trial. JAMA 1999;282:2305-2312. (Pubitemid 30013061)
19. Noble S, Goa KL. Adefovir dipivoxil. Drugs 1999;58:479-487; discussion 488-1479
20. Fisher EJ, Chaloner K, Cohn DL, Grant LB, Alston B, Brosgart CL, et al. The safety and efficacy of adefovir dipivoxil in patients with advanced HIV disease: a randomized, placebo-controlled trial. AIDS 2001;15:1695-1700. (Pubitemid 32918124)
21. Vigano M, Lampertico P, Lavarone M, Tontini GE, Facchetti F, Colombo M. High risk of renal impairment and arterial hypertension during long-term adefovir and lamivudine combination therapy in patients with lamivudine-resistant chronic hepatitis B. HEPATOLOGY 2008;48(Suppl 1):897A.